FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A
The U.S. Food and Drug Administration (FDA) has lifted…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been…
New $100M Program Aims to Improve Diversity in Clinical Trials
A new $100-million program aims to improve the diversity of…
Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU
Janssen is seeking to extend approval of its…
Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19
Myeloma UK is calling for more data transparency…
Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715
ALLO-715, an investigational donor-derived CAR T-cell therapy…
